A series of nine related aromatic monocarboxylic acids (ACAs) previously shown to inhibit muscle membrane chloride conductance (GCl) selectively in the rat were studied for their ability to produce myotonia. All nine induced characteristic repetitive electrical activity and delayed relaxation in isolated muscle, although the concentrations required for this action varied widely. In each case, myotonia was observed at concentrations that correlated closely with previously determined half-maximal concentrations for inhibition of GCl. Intracellular recordings from muscle made myotonic with ACA revealed prolonged latencies at rheobase, multiple driven spikes, and self-sustaining repetitive activity similar to that previously reported in hereditary goat myotonia. Phase-plane diagrams of membrane action potentials recorded after exposure to the most effective of these compounds suggested little effect on the voltage-dependent sodium system. The changes seen could be duplicated by simple removal of chloride ion. The expression of repetitive electrical activity in the presence of low membrane GCl depends on ambient temperature and on the concentration of calcium ion. Increasing temperature and decreasing Ca++ predispose toward myotonic activity; converse conditions inhibit myotonia. Myotonia induced by ACA is inhibited by concentrations of diphenylhydantoin that are clinically effective in controlling hereditary myotonia in humans.

Download full-text PDF

Source
http://dx.doi.org/10.1002/ana.410040411DOI Listing

Publication Analysis

Top Keywords

myotonia induced
8
repetitive electrical
8
electrical activity
8
myotonia
6
pathophysiology myotonia
4
myotonia produced
4
produced aromatic
4
aromatic carboxylic
4
carboxylic acids
4
acids series
4

Similar Publications

At 4 months of age, a male dog was presented with a complaint of a stiff gait following a startle response. Neurological examination revealed no deficits, but clinical myotonia was easily induced upon requesting the patient to jump. Additionally, myotonia of the upper lip muscles was observed upon manipulation.

View Article and Find Full Text PDF
Article Synopsis
  • Brody disease (BD) is an ultra-rare genetic disorder affecting muscle function due to a deficiency in the SERCA protein, leading to stiffness and delayed muscle relaxation after exercise.
  • There are currently no specific therapies or mouse models for BD, making it an orphan disease; however, bovine congenital pseudomyotonia serves as a mammalian model to study the condition.
  • This study focuses on the "acctq206" zebrafish variant as a potential model for testing new treatments, emphasizing the need for preclinical research before moving to human clinical trials.
View Article and Find Full Text PDF

Neuromyotonia.

Handb Clin Neurol

August 2024

UCL Queen Square Institute of Neurology, Department of Neuroinflammation, and National Hospital for Neurology and Neurosurgery, London, United Kingdom. Electronic address:

Article Synopsis
  • * The disorder can be genetic or acquired, with a significant focus on autoimmune causes such as CASPR2 and LGI1 antibody diseases, Guillain-Barré syndrome, and others.
  • * Treatment strategies involve addressing any underlying tumors, using immune suppression therapies for autoimmune cases, and sodium channel blockers for symptom management.
View Article and Find Full Text PDF

Mouse models of non-dystrophic and dystrophic myotonia exhibit nociplastic pain-like behaviors.

bioRxiv

June 2024

Department of Pharmacology and Therapeutics, McKnight Brain Institute, and Pain and Addiction Therapeutics (PATH) Collaboratory, University of Florida College of Medicine, Gainesville, FL 32610, USA.

Pain is a prominent and debilitating symptom in myotonic disorders, yet its physiological mechanisms remain poorly understood. This study assessed preclinical pain-like behavior in murine models of pharmacologically induced myotonia and myotonic dystrophy type 1 (DM1). In both myotonia congenita and DM1, impairment of the gene, which encodes skeletal muscle voltage-gated CLC-1 chloride channels, reduces chloride ion conductance in skeletal muscle cells, leading to prolonged muscle excitability and delayed relaxation after contraction.

View Article and Find Full Text PDF

Expert opinion on mexiletine treatment in adult patients with myotonic dystrophy.

Arch Cardiovasc Dis

June 2024

Cardiology Department, La Timone Hospital, CHU de Marseille, AP-HM, 13385 Marseille, France; C2VN, Aix-Marseille Université, 13005 Marseille, France.

In France, mexiletine - a class I antiarrhythmic drug - can be prescribed for the symptomatic treatment of myotonia of the skeletal muscles in adult patients with myotonic dystrophy under a compassionate use programme. Mexiletine is used according to its summary of product characteristics, which describes its use for myotonia treatment in adult patients with non-dystrophic myotonia, a different neuromuscular condition without cardiac involvement. A cardiac assessment is required prior to initiation and throughout treatment due to potential proarrhythmic effects.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!